The study was terminated due to the impacts of COVID-19 on patient safety and enrollment.

The purpose of this study is to characterize the natural history of leukocyte chemotactic factor 2 amyloidotic (ALECT2) disease. In this observational study participants with ALECT2 disease will be enrolled. Participants, who have already reached end-stage renal disease (ESRD), will provide retrospective chart review data and biological specimens at baseline only. Other participants, in addition to retrospective chart review, will be followed prospectively.

Refer to www.studyALECT2.com

Inclusion Criteria:

• Males and females, age 18 years or older;
• Renal biopsy-proven diagnosis of ALECT2;
• For patients with kidney disease that could be due to ALECT2, a renal biopsy may be obtained to confirm ALECT2 diagnosis.

Exclusion Criteria:

- There are no exclusion criteria for this observational study.

Participants with biopsy-proven ALECT2.